Premium
Monopolar radiofrequency treatment of human eyelids: A prospective, multicenter, efficacy trial
Author(s) -
Biesman Brian S.,
Baker Sterling S.,
Carruthers Jean,
Silva Hector Leal,
Holloman Erin L.
Publication year - 2006
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.20452
Subject(s) - medicine , multicenter study , clinical trial , prospective cohort study , surgery , randomized controlled trial
Background/Objective To evaluate the efficacy of a novel 0.25 cm 2 monopolar radiofrequency (RF) treatment tip for aesthetic rejuvenation of the eyelids. Study Design/Materials and Methods This was a prospective, multicenter trial in which the eyelids of 72 patients were treated. Patients underwent a single treatment session and were then followed on a serial basis for 6 months. Cutaneous anesthesia was not required to perform the treatments. Assessments were made by the treating physician, the subjects, and by masked physician observers evaluating photographs taken at each data point. Results Upper eyelid tightening and reduction of hooding was noted in 88 and 86% of subjects, respectively. Lower eyelid tightening was noted in 71–74% of subjects. The majority of patients treated achieved at least up to 25% improvement while a smaller percentage achieved more dramatic results. There was no correlation between the amount of energy applied to the eyelids and the clinical outcome. There were no serious adverse sequelae. Conclusion Human eyelids can be safely treated with monopolar RF energy delivered via a novel 0.25 cm 2 treatment tip. Using this technology non‐invasive eyelid rejuvenation was achieved in the majority of subjects treated. The factors differentiating those patients who achieve the most impressive changes from others remain unclear. Further development and testing of this technology is warranted. Lasers Surg. Med. 38:890–898, 2006. © 2006 Wiley‐Liss, Inc.